# reload+after+2024-01-21 18:43:58.805922
address1§16305–36th Avenue North
address2§Suite 100
city§Minneapolis
state§MN
zip§55446
country§United States
phone§763 392 0767
website§https://www.celcuity.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
fullTimeEmployees§45
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Brian F. Sullivan', 'age': 61, 'title': 'Co-Founder, Chairman & CEO', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 105769, 'exercisedValue': 0, 'unexercisedValue': 2450180}, {'maxAge': 1, 'name': 'Dr. Lance G. Laing Ph.D.', 'age': 61, 'title': 'Co-Founder, Chief Science Officer, VP, Secretary & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 325385, 'exercisedValue': 0, 'unexercisedValue': 874383}, {'maxAge': 1, 'name': 'Ms. Vicky  Hahne', 'age': 57, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 210000, 'exercisedValue': 0, 'unexercisedValue': 520665}, {'maxAge': 1, 'name': 'Dr. John R. MacDonald Dabt, Ph., Ph.D.', 'age': 68, 'title': 'Senior Vice President of R&D', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sheri  Smith', 'title': 'Acting Head of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Igor  Gorbatchevsky M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§7
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.686
currency§USD
dateShortInterest§1702598400
forwardEps§-2.86
pegRatio§-0.17
exchange§NCM
quoteType§EQUITY
shortName§Celcuity Inc.
longName§Celcuity Inc.
firstTradeDateEpochUtc§1505914200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3823f702-835a-3171-9799-5e1fe94326a8
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§20.0
targetMeanPrice§24.25
targetMedianPrice§25.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§10.538
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
